Search results for "Patient-reported outcomes"

showing 10 items of 19 documents

Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on …

2020

Contains fulltext : 229532.pdf (Publisher’s version ) (Open Access) Patients with sarcoma experience many physical and psychological symptoms, adversely affecting their health-related quality of life (HRQoL). HRQoL assessment is challenging due to the diversity of the disease. This review aims to unravel the heterogeneity of HRQoL of patients with sarcoma with regard to tumour location and to summarise the used measures in research. English-language literature from four databases published between January 2000 and April 2019 was reviewed. Studies that described adult sarcoma HRQoL outcomes were included and classified according to primary sarcoma location. Eighty-seven articles met the incl…

AdultCancer Researchmedicine.medical_specialtyConstitutional symptomsPopulationbone sarcomaSoft Tissue NeoplasmsReviewBone Sarcomalcsh:RC254-282Quality of lifeInternal medicineSurveys and QuestionnairesMedicineHumans1506educationeducation.field_of_studyOsteosarcomabusiness.industrySoft tissue sarcomaSarcomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitieshealth-related quality of lifeSystematic reviewOncologypatient-reported outcomessoft tissue sarcomaQuality of LifeSarcomabusinessPsychosocialRare cancers Radboud Institute for Health Sciences [Radboudumc 9]ESMO Open
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression : Baseline patient characteristics

2021

Journal of affective disorders 283, 115-122 (2021). doi:10.1016/j.jad.2020.11.124

AdultMaleDisease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic status; Adult; Cohort Studies; Europe; Female; Humans; Male; Middle Aged; Quality of Life; Depressive Disorder Major; Depressive Disorder Treatment-Resistantmedicine.medical_specialtyHealth-related quality of lifeSocio-economic statusMajor depressive disorderCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineQuality of lifeObservational studyInternal medicinemedicineHumansMedical historyDepression (differential diagnoses)Disease burdenDepressive DisorderDepressive Disorder MajorPatient-reported outcomesDisease burden Health-related quality of life Major depressive disorder Observational study Patient-reported outcomes Socio-economic statusbusiness.industryTreatment-ResistantMajorDisease burdenMiddle Agedmedicine.disease030227 psychiatry3. Good healthEuropePsychiatry and Mental healthClinical PsychologyPresenteeismQuality of LifeMajor depressive disorderFemalebusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort study
researchProduct

Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant …

2016

Background The management of bloating is unclear and its relationship with patients' well-being and treatment satisfaction independent of other abdominal symptoms is uncharacterized. We evaluated the association of bloating with patient-reported outcomes. Methods Thirty-nine centers for functional gastrointestinal disorders joined the laxative inadequate relief survey. We enrolled 2203 consecutive outpatients with functional constipation (FC) or constipation-predominant irritable bowel syndrome (IBS-C) in two cross-sectional waves. Both wave 1 and 2 included the SF-12, the patient assessment of constipation-symptoms (PAC-SYM), and the treatment satisfaction questionnaire for medication (TSQ…

AdultMaleQuality of lifemedicine.medical_specialtyConstipationCross-sectional studyPhysiologyBloating; Chronic constipation; Functional constipation; Irritable bowel syndrome; Patient-reported outcomes; Quality of life; Treatment satisfaction; Physiology; Endocrine and Autonomic Systems; GastroenterologyBloating; Chronic constipation; Functional constipation; Irritable bowel syndrome; Patient-reported outcomes; Quality of life; Treatment satisfaction; Adult; Constipation; Cross-Sectional Studies; Female; Flatulence; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Prevalence; Quality of Life; Surveys and QuestionnairesEndocrine and Autonomic System03 medical and health sciences0302 clinical medicineBloatingQuality of lifeSurveys and QuestionnairesInternal medicinePrevalencemedicineFlatulenceHumansIrritable bowel syndromePatient-reported outcomeChronic constipationSettore MED/12 - GastroenterologiaPatient-reported outcomesTreatment satisfactionBloating; Chronic constipation; Functional constipation; Irritable bowel syndrome; Patient-reported outcomes; Quality of life; Treatment satisfaction; Adult; Constipation; Cross-Sectional Studies; Female; Flatulence; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Prevalence; Quality of Life; Surveys and Questionnaires; Physiology; Endocrine and Autonomic Systems; GastroenterologyEndocrine and Autonomic Systemsbusiness.industryChronic constipationBloatingSettore MED/09 - MEDICINA INTERNAGastroenterologyMiddle Agedmedicine.diseaseIrritable bowel syndromeSettore MED/18 - Chirurgia GeneraleCross-Sectional StudiesTolerability030220 oncology & carcinogenesisPhysical therapyFunctional constipationFemale030211 gastroenterology & hepatologymedicine.symptombusinessConstipationFunctional constipation
researchProduct

Ten-year follow-up of health-related quality of life among ambulatory persons with multiple sclerosis at baseline

2016

Purpose The aim of this 10-year follow-up study was to determine changes in health-related quality of life (HRQoL) over time among ambulatory persons with MS (PwMS) at the baseline using generic and disease-specific instruments. Methods Of 109 independently walking PwMS included in a population-based study in 2002, 77 (70.6 %) were re-assessed in 2012. HRQoL was captured using the 36-Item Short Form Survey Instrument (RAND-36), 15D instrument (15D), and the Multiple Sclerosis Quality of Life-54 (MSQOL-54). Repeated-measures ANOVA and effect size (ES) calculations (Cohen’s d) were used in the statistical analysis. Results The RAND-36 physical health composite score (p = 0.003, ES = 0.26) and…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime FactorsPopulationelämänlaatu03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifeMS-tautiSickness Impact ProfileSurveys and QuestionnairesmedicineHumans030212 general & internal medicinePatient Reported Outcome MeasureseducationSocial functioningAgedHealth related quality of lifeAged 80 and overeducation.field_of_studySexual functioningbusiness.industryMultiple sclerosisPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseasepatient-reported outcomesAmbulatoryPhysical therapyFemaleAnalysis of variancebusinessterveys030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey

2013

WOS: 000335253700001

AdultQuality of lifemedicine.medical_specialtyActivities of daily livingInternationalityAdolescentDiseaseShort staturechemistry.chemical_compoundWheelchairQuality of lifeElosulfase alfaMedicineHumansGenetics(clinical)Pharmacology (medical)ChildGenetics (clinical)FatigueMobilityMedicine(all)Pain measurementPatient-reported outcomesbusiness.industryData CollectionResearchMucopolysaccharidosis IVGeneral MedicineGaithumanitiesEQ-5D-5LchemistryWheelchairsJoint painPhysical therapymedicine.symptombusinessMorquio A syndromeOrphanet Journal of Rare Diseases
researchProduct

Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults

2020

Abstract Background In 2016, an expert working group was convened under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and formulated consensus recommendations for the conduct of clinical trials for drugs to prevent or treat sarcopenia. Aims The objective of the current paper is to provide a 2020 update of the previous recommendations in accordance with the evidence that has become available since our original recommendations. Methods This paper is based on literature reviews performed by members of the ESCEO working group and followed up with face to face meetings organized for the whole group to make amendments and discuss…

AgingSarcopeniaGeriatrics & GerontologyStandardizationDiseaseReviewRecommendationsFace-to-face0302 clinical medicineQUALITY-OF-LIFEGAIT SPEEDClinical trial; Drug registration; Guidelines; Recommendations; Sarcopenia; Treatment; Aged; Humans; Muscle Strength; Osteoarthritis; Osteoporosis; Pharmaceutical Preparations; Sarcopenia030212 general & internal medicineMUSCLE MASSDIETARY-PROTEINClinical trialPhysical limitationsPharmaceutical Preparations/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPatient-reported outcomeGRIP STRENGTHLife Sciences & Biomedicinemedicine.medical_specialtyNUTRITIONAL-STATUSBODY-COMPOSITION030209 endocrinology & metabolismGuidelines03 medical and health sciencesClinical trial · Sarcopenia · Guidelines · Recommendations · Drug registration · TreatmentSDG 3 - Good Health and Well-beingOsteoarthritismedicineHumansMuscle StrengthDrug registrationAgedScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseComorbidityClinical trialTreatmentSarcopeniaPATIENT-REPORTED OUTCOMESPhysical therapyOsteoporosisGeriatrics and GerontologyPHYSICAL PERFORMANCEbusinessAging Clinical and Experimental Research
researchProduct

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Pract…

2022

Digital health tools are increasingly being used in cancer care and may include electronic patient-reported outcome (ePRO) monitoring systems. We examined physicians’ perceptions of usability and clinical utility of a digital health tool (GIMEMA-ALLIANCE platform) for ePRO monitoring in the real-life practice of patients with hematologic malignancies. This tool allows for the collection and assessment of ePROs with real-time graphical presentation of results to medical staff. Based on a predefined algorithm, automated alerts are sent to medical staff. Participating hematologists completed an online survey on their experience with the platform. Of the 201 patients invited to participate betw…

Cancer Researchhematologydigital healthleukemialymphomaSettore MED/15patient-reported outcomes (PROs)digital health hematology leukemia lymphoma multiple myeloma patient-reported outcomes (PROs) quality of life symptomsmultiple myelomaOncologyquality of lifesymptomsdigital health; hematology; leukemia; lymphoma; multiple myeloma; patient-reported outcomes (PROs); quality of life; symptoms
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics: Patient character…

2021

Background: Treatment resistant depression (TRD; failure to respond to ≥2 treatments) affects ~20% of patients with major depressive disorder (MDD). Real-world data could help describe patient characteristics and TRD disease burden, to assess the unmet needs of TRD patients in Europe. Methods: This observational study collected data from adults with moderate to severe TRD initiating a new treatment for depression, according to local standards of care. At baseline, socio-demographic characteristics, medical history, prior and current treatments were recorded. Disease severity, health-related quality of life (HRQoL), functionality and productivity were assessed. Results: Overall, 411 eligible…

Disease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic statusPatient-reported outcomesHealth-related quality of lifeObservational studySocio-economic statusDisease burdenMajor depressive disorderPsiquiatria
researchProduct

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.

2018

Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/kappa monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20-50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/mu L or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific clu…

Drugmedicine.medical_specialtymedia_common.quotation_subjectReview030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato Respiratoriopatient-reported outcomeasthma; patient-reported outcomes; personalized medicine; reslizumabPathogenesis030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineReslizumabInternal medicinemedicineAsthmatic patientPathologicalAsthmamedia_commonbusiness.industrypersonalized medicineasthmamedicine.diseasereslizumabpatient-reported outcomesPersonalized medicinebusinessMepolizumabmedicine.drugPatient related outcome measures
researchProduct

Disability in moderate chronic obstructive pulmonary disease: Prevalence, burden and assessment-results from a real-life study

2014

<b><i>Background:</i></b> The role of disability and its association with patient-reported outcomes in the nonsevere forms of chronic obstructive pulmonary disease (COPD) has never been explored. <b><i>Objectives:</i></b> The aim of this study was to assess, in a cross-sectional real-life study, the prevalence and degree of disability in moderate COPD patients and to assess its association with health status, illness perception, risk of death and well-being. <b><i>Methods:</i></b> Moderate COPD outpatients attending scheduled visits were involved in a quantitative research program using a questionnaire-based data collec…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveActivities of daily livingCross-sectional studyHealth StatusPulmonary diseaseChronic obstructive pulmonary disease; Disability; Patient-reported outcomes; Activities of Daily Living; Aged; Cross-Sectional Studies; Disability Evaluation; Female; Health Status; Humans; Italy; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Pulmonary and Respiratory MedicineSettore MED/10 - Malattie Dell'Apparato RespiratorioChronic obstructive pulmonary disease; Disability; Patient-reported outcomes; Activities of Daily Living; Aged; Cross-Sectional Studies; Disability Evaluation; Female; Health Status; Humans; Italy; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Pulmonary and Respiratory Medicine; Medicine (all)Illness perceptionsPulmonary DiseasePulmonary Disease Chronic ObstructiveDisability EvaluationActivities of Daily LivingMedicineHumansDisease burdenAgedCOPDDisabilityPatient-reported outcomesbusiness.industryMedicine (all)Chronic obstructive pulmonary diseaseMiddle Agedmedicine.diseaseCross-Sectional StudiesItalyPhysical therapyFemaleRisk of deathbusinessLife study
researchProduct